Panakeia

🎉 Today we launch PANProfiler Colon! 🎉 PANProfiler Colon is an AI-driven software solution for profiling of Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) entirely digitally and directly from Haematoxylin and Eosin (H&E)-stained images of colon cancer tissue samples. 🧬 PANProfiler Colon leverages AI and proprietary insights into colorectal cancer biology to determine MSI/dMMR status in minutes 🏥 Registered for use in the UK, PANProfiler Colon is already deployed in multiple hospitals 📈 Results of a blinded multi-site validation study of PANProfiler Colon will be presented at this year’s American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.  Read the full announcement here: https://lnkd.in/exzeyzYx #AI #multiomics #biomarkers #moleculardiagnostics #precisionmedicine #personalisedmedicine #launch #colorectalcancer #coloncancer #cancer

Happy new year! We kicked off 2025 with a productive week of meetings in Delhi, India. Our CEO and founder Pahini Pandya met with a variety of government and industry stakeholders to discuss the adoption of Panakeia’s AI-enabled molecular profiling solutions in India. Carrying the momentum from a strong first week of 2025, we will be on the ground in San Francisco for JPM week showcasing Panakeia’s offering and holding meetings with industry stakeholders. We will also be presenting interesting data on our products later in the month at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. We will finish the month in India, where we will hold further discussions with industry stakeholders. Check out the events we will be attending in January here: https://lnkd.in/etQtn4uY Get in touch to arrange an in person meeting in San Francisco or India this month.

Will you be in San Francisco for JPM week? Our CEO and Founder, Pahini Pandya will be presenting at the Springboard Enterprises Healthcare & Technology Accelerator Showcase and meeting with stakeholders through the week. Get in touch to arrange a meeting in person in San Francisco!

What a transformative 2024! As we close the year, we’re proud to share how Panakeia has advanced its mission of making precision medicine accessible worldwide through AI-powered cancer diagnostics. Key Highlights: ✅Our flagship breast cancer solution demonstrated industry-leading performance, receiving recognition for its “impressive levels of performance” in clinical settings. We shared these groundbreaking results with Leeds Teaching Hospitals NHS Trust at American Association for Cancer Research Annual meeting showing how rapid molecular profiling can accelerate treatment decisions for cancer patients. ✅Our value proposition, delivered through rapid, easy-to-use digital molecular profiling, resonated strongly across 15+ major industry forums. We led/participated in, including expert panels and strategic roundtables with both clinical and pharmaceutical leaders. ✅As part of our commitment to patient safety and clinical excellence, we collaborated with Friends of Cancer Research and industry leaders to establish robust standards for AI diagnostic tools, ensuring our solutions deliver maximum benefit to patients while maintaining the highest safety standards. ✅Our innovation in healthcare AI continues to represent the best of UK healthtech globally, supported by Innovate UK, Grow London London & Partners and the Department for Business and Trade. Looking ahead to 2025, we’re excited to build on this momentum to serve more patients and healthcare providers globally. Our growing pipeline of innovations promises to further transform cancer diagnostics, making precision medicine more accessible and timely for patients worldwide. Thank you to our partners, supporters, and especially the healthcare providers who trust us to help deliver better patient care. Here’s to an impactful 2025! #HealthTech #CancerDiagnostics #AI #PrecisionMedicine #Healthcare

#JPM25 week is just around the corner and we will be in San Francisco pitching Panakeia at Springboard Enterprises Healthcare & Technology Accelerator Demo Day Showcase Event taking place on January 14th 9-11am PT at the Deloitte offices in San Francisco. It has been a privilege to be part of the accelerator program. A key highlight has been getting access to incredible mentors and networks to grow our business and drive adoption of our ground-breaking AI-enabled multi-omic biomarker profiling platform in the US. We invite you to join us and learn how we bring rapid, digital, intuitive molecular profiling solutions to every clinic, helping healthcare professionals worldwide make informed decisions for their patients. #JPM25 #womenininnovation #moleculardiagnostics #AI #artificialintelligence #cancerdiagnostics #biomarkers #precisionmedicine 

Determining a breast cancer patient’s HER2 status from a biopsy sample is inarguably one of the most consequential tests at the start of the treatment journey as it determines the subsequent therapeutic options available, most importantly those eligible for treatment with novel antibody-drug conjugates. AI-enabled digital pathology solutions have a big role to play in expediting determination of HER2 status, especially when HER2 expression levels are low and status is difficult to determine by eye.  At this year’s San Antonio Breast Cancer Symposium we are proud to have co-authored a study conducted as part of a research partnership to describe and evaluate the agreement of HER2 biomarker assessment across independently developed AI models put together by Friends of Cancer Research. The study concluded that while variability exists, these models routinely determined HER2 status successfully. We are filled with hope and anticipation for the continuation of this study which will inform the future development of AI models and set a gold standard for the ever-evolving landscape in the context of clinical application.   Abstract title: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project  Abstract no: P2-02-18 Booth: #1433 in the Exhibit Hall, Halls 2-3 Time and date: Poster Session 2, 5:30 – 7:00 p.m. CST, Wednesday, December 11 Read the full abstract here: https://lnkd.in/enX25nD9 #SABCS24 #breastcancer #biomarker #HER2 #cancer #precisionmedicine #moleculardiagnostics

Thank you, Duke Capital Partners for your continued support in our mission to usher a new era of precision treatments for all by bringing rapid, digital, intuitive molecular profiling solutions to every clinic, helping healthcare professionals worldwide make informed decisions for their patients.

This week we are in San Francisco attending the 3rd Danaher Corporation Annual Summit titled “AI-driven Predictive R&D: from Promise to Practice”. This year’s event focuses on how generative and predictive AI, data integration, and knowledge generation are revolutionising biopharmaceutical research and development. Our founder and CEO Pahini Pandya will be on the ground to discuss with industry experts, fellow innovators and other industry stakeholders Panakeia’s contribution to the field. Our  AI-enabled multi-omics platform can detect cancer biomarkers, informing treatment decisions for healthcare professionals and accelerating drug development by enabling patient screening, stratification and monitoring. Find out more about the event here: https://lnkd.in/ek7yB4nN #researchanddevelopment #moleculardiagnostics #AI #precisionmedicine

It’s been six wonderful years since Panakeia was founded. We are thankful for our wonderful team and what we have collectively achieved. Our 6th birthday highlights include: 🧬 Developing a ground-breaking platform for multi-omic biomarker identification for more than 30 cancer types. 🔬 Having two clinical products approved for biomarker identification. 🏥Our products deployed in hospitals in the UK and producing best-in-class results. 🚀 Building a strong research team that has produced state of the art AI-enabled technology. 📈 Growing our team every year bringing in world class talent, driving our mission of bringing rapid, cost-effective molecular profiling to every clinic to help healthcare professionals worldwide make informed decisions for their patients and usher a new era of precision treatments for all. We look forward to many more years of innovation, excellence and camaraderie.

We have landed in India where over the next few days we will engage with a variety of stakeholders in India’s healthcare industry in Mumbai, Bengaluru and Delhi. We are privileged to be part of the 10th UK-India Healthcare Trade Mission organised by the UK Government's Department for Business and Trade and led by Professor Sir Stephen Powis, National Medical Director of NHS England, alongside other innovative UK companies. India is a fast growing economy with an advanced healthcare system which is currently embarrassing digital diagnostics and personalised medicine, making it one of the leaders in the digital transition of healthcare. We look forward to discussing the capabilities of our AI-enabled multi-omics platform for detecting cancer biomarkers, informing treatment decisions for healthcare professionals and accelerating drug development by enabling patient screening, stratification and monitoring. Find out more about the mission here: https://lnkd.in/eX9m7kBU (edited) #trademission #innovation #healthtech #AI #precisionmedicine #biomarkers #personalisedtreatment #digitalhealth